Nomura Asset Management Co. Ltd. Has $19.48 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Nomura Asset Management Co. Ltd. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 82,785 shares of the biopharmaceutical company’s stock after selling 2,660 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $19,480,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cerity Partners LLC boosted its position in Alnylam Pharmaceuticals by 133.6% in the third quarter. Cerity Partners LLC now owns 13,019 shares of the biopharmaceutical company’s stock valued at $3,581,000 after buying an additional 7,445 shares in the last quarter. Quantbot Technologies LP boosted its holdings in shares of Alnylam Pharmaceuticals by 1,754.5% during the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 193 shares in the last quarter. Bridgewater Associates LP bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $551,000. Captrust Financial Advisors raised its position in Alnylam Pharmaceuticals by 34.4% in the third quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company’s stock valued at $1,329,000 after purchasing an additional 1,237 shares during the last quarter. Finally, True Wealth Design LLC boosted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 0.9 %

NASDAQ:ALNY opened at $268.46 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock has a market capitalization of $34.92 billion, a price-to-earnings ratio of -123.71 and a beta of 0.39. The firm has a fifty day simple moving average of $259.86 and a two-hundred day simple moving average of $260.53.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ALNY shares. Scotiabank raised their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a report on Friday, March 21st. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research note on Friday, March 21st. Chardan Capital reissued a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Wells Fargo & Company increased their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. Finally, Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $312.30.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,234 shares of company stock valued at $19,958,097. Company insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.